Novoic is a clinical stage biotechnology company developing algorithms to detect neurological diseases such Alzheimer’s disease in their preclinical stages, by analysing audio-linguistic patterns of speech.

Building on decades of research, the company is currently testing these algorithms in the clinic, to bring the first clinically viable speech-based algorithms to market.

The company is working with the Alzheimer’s Drug Discovery Foundation and Gates Ventures to develop a global standard for speech biomarkers, and have been backed by the NHS–as the world’s only speech company–to test out their algorithms in +5 common neurological indications.